First Results From the Independent Study: Impact of Home Blood Pressure Measurement on Office Blood Pressure Targets With Angiotensin Ii Receptor Blocker and Indapamide Combination

Objective: This study evaluates whether regular home blood pressure measurement supports achieving the first target office blood pressure per the current 2023 ESH guidelines (<140/80 mmHg) in patients treated with valsartan or telmisartan with indapamide in a new single-pill combination. Design and method: The interim results from this ongoing international, non-interventional, prospective, multicentre study include 715 hypertensive patients from four European countries, observed for 10–16 weeks, data collected at baseline and at two follow-up visits. 691 patients were grouped by home blood pressure measurement habits: regular (N=412; 3 days or more/week before visit) and non-regular (N=279). This analysis covers only the valsartan and indapamide 160/1.5 mg combination. Results: Of 715 patients (53.3% female; mean age 61.9±11.9 years), 60.3% had 1 or more comorbidity, 39.7% none, 41% one, 14.3% two, 4.5% three, and 0.6% four. Hyperlipidaemia (52.7%), diabetes (20.8%), metabolic syndrome (9.5%), and chronic kidney disease (2.1%) were most common. Hypertension grades: 43.1% Grade 1, 44.7% Grade 2, and 12.2% Grade 3. Blood pressure control was achieved in 87% per previous guidelines and 38.8% per 2023 ESH target, highlighting challenges linked to the lower diastolic threshold. Target achievement was comparable between regular and non regular home blood pressure measurement (previous guidelines: 85.4% vs. 89.2%; new guidelines: 38.3% vs. 39.4%). For the home blood pressure target (<135/85 mmHg), the proportion controlled increased from 72.6% at visit 2 to 82.8% at visit 3, with mean home blood pressure at visit 3 reaching 126±8.5/78.4±6.1 mmHg. Subgroup analyses revealed statistically nonsignificant differences across demographic or clinical groups. A positive trend favouring regular home blood pressure measurement appeared in Grade 3 patients and those 71 or more years, though statistically nonsignificant. The treatment remained metabolically neutral, with no relevant changes in glucose, lipid profile, or serum creatinine among patients with stable comorbidity therapy.Conclusions: The valsartan and indapamide single pill combination achieved high blood pressure control across diverse hypertensive population, showing consistent effectiveness regardless of home measurement regularity, while regular monitoring showed favourable trends in older, high risk patients where tailored management and closer follow up could further support outcomes.